Publications

It was agreed that any research that CONVINCE generates is based on a prior consensus of all members of the CONVINCE Scientific Committee. 

 

Vernooij, R.W.M., Bots, M.L., Strippoli, G.F.M., Canaud, B., Cromm, K., Woodward, M., Blankestijn, P.J. (2022) CONVINCE in the context of existing evidence on haemodiafiltration Nephrol Dial Transplant 2022 37(6): 1006-1013.  doi: 10.1093/ndt/gfac019. 

Blankestijn, P.J., Fischer, K.I., Barth, C., Cromm, K., Canaud, B., Davenport, A., ...Rose, M. (2020). Benefits and harms of high-dose haemodiafiltration versus high-flux haemodialysis: the comparison of high-dose haemodiafiltration with high-flux haemodialysis (CONVINCE) trial protocol. BMJ OPEN, 10 (2), doi:10.1136/bmjopen-2019-033228

Kathrin I. Fischer, Peter J. Blankestijn, Krister Cromm, Michiel L. Bots, Claudia Barth, Bernard Canaud, Jörgen Hegbrant, Giovanni Strippoli, Andrew Davenport, Mark Woodward, Matthias Rose on behalf of the CONVINCE Consortium.  Assessing the Patient’s Perspective in End-stage Kidney Disease –ADomain-Guided Approach Applied in the CONVINCE Trial. Poster presentation at 26th Annual Conference ISOQOL, 2019. 

Fischer KI, Blankestijn PJ, Cromm K, Bots ML, Barth C, Canaud B, Hegbrant J, Macário F, Marrón B, Török M, Davenport A, Lee MM, Strippoli GFM, Wohn L, Woodward M, Rose M. Assessment of generic and dialysis-related fatigue – Identification of individual trajectories and investigation of ecological validity. Quality of Life Research. 2020;29(S1): S180.  https://doi.org/10.1007/s11136-020-02626-y    link to abstract.  Poster presentation at 27th Annual Conference ISOQOL, 2020.

Blankestijn, P.J., Grooteman, M.P., Nube, M.J. and Bots, M.L. (2018).  Clinical evidence on haemodiafiltration.  Nephrology Dialysis Transplantation 33, iii53-iii58. doi: 10.1093/ndt/gfy218.